Lazertinib (YH25448): Mechanism of Action

Lazertinib (YH25448) MOA:Targeting EGFR/MAPK Signaling Pathway for First-Line Treatment of EGFR-Mutated Advanced NSCLC

🎯 check Lazertinib (YH25448) product page

Lazertinib (YH25448) is a kinase inhibitor. It affects cMET signaling, by reducing cMET receptor density, to promote ADCC.

Primary Applications and Mechanism of Action